# To Compare the Safety and Pharmacokinetics of PT105 With PT105R in Healthy Postmenopausal Female Volunteers

> **NCT04783636** · PHASE1 · UNKNOWN · sponsor: **Peptron, Inc.** · enrollment: 40 (estimated)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** leuprorelin acetate 3.75mg

## Key facts

- **NCT ID:** NCT04783636
- **Lead sponsor:** Peptron, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-03-11
- **Primary completion:** 2021-07-20
- **Final completion:** 2021-07-20
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2021-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04783636

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04783636, "To Compare the Safety and Pharmacokinetics of PT105 With PT105R in Healthy Postmenopausal Female Volunteers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04783636. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*